Immune therapies with bispecific antibodies and conjugated antibodies for BCP-ALL have replaced standard of care chemotherapy in R/R ALL,29 led for the first time to marketing authorization for MRD-positive ALL30 and are increasingly being tested in first-line trials. This evidence concerns the gene OPN1SW and acute lymphoblastic leukemia.